Skip to main content
DR REDDYS LABORATORIES LTD logo

DR REDDYS LABORATORIES LTD — Investor Relations & Filings

Ticker · RDY ISIN · US2561352038 LEI · 335800OVDPY3DVZR2798 BSE.NS Manufacturing
Open in API
Filings indexed 2,318 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country IN India
Listing BSE.NS RDY

About DR REDDYS LABORATORIES LTD

https://www.drreddys.com/

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company focused on providing affordable and innovative medicines. The company's core activities include the development, manufacturing, and marketing of a broad portfolio of products. This portfolio encompasses Active Pharmaceutical Ingredients (APIs), generic and branded-generic formulations, over-the-counter (OTC) products, and biologics. In addition to its significant presence in the generics market, the company invests in the research and development of novel molecules and proprietary products, with a focus on therapeutic areas such as dermatology and neurology. Dr. Reddy's is also committed to sustainable operations, actively working to reduce its environmental footprint through initiatives in water conservation, waste reduction, and decarbonisation.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings Classification · 15% confidence The document is a letter from Dr. Reddy’s Laboratories to the stock exchanges enclosing a copy of a newspaper notice concerning the transfer of unclaimed dividends and underlying equity shares to the Investor Education and Protection Fund (IEPF). It is not an actual financial report or dividend payment notice but a general regulatory announcement to the exchanges, falling under miscellaneous regulatory filings. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-27 English
Copies of newspaper publication
Regulatory Filings Classification · 75% confidence The document is a letter to stock exchanges enclosing a newspaper notice about transfer of unclaimed dividends and equity shares to the Investor Education and Protection Fund under Section 124 of the Companies Act. It does not present financial results, management discussion, or an actual report, nor is it a dividend amount declaration, merger, or board change. It is a compliance/regulatory announcement to the exchanges. Therefore, it best fits the fallback category for miscellaneous regulatory filings (RNS).
2026-05-27 English
Transcript of Earnings call recordings held on May 12, 2026
Report Publication Announcement Classification · 84% confidence The document is a brief cover letter to stock exchanges notifying them that the earnings call transcript for Q4 FY26 is enclosed and uploaded online. It does not contain the actual transcript, only an announcement that the report is available. Under the “menu vs meal” rule, this is a Report Publication Announcement (RPA), not the call transcript itself.
2026-05-18 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a letter addressed to stock exchanges and references the transcript of an earnings call conducted on May 12, 2026, for the quarter and financial year ended March 31, 2026. It states that the transcript is enclosed and also available on the company's website. The document is short (1404 characters) and primarily serves as a notification and provision of the transcript rather than the transcript itself. According to the rules, a transcript of an earnings call is classified as a Call Transcript (CT). Since the transcript is enclosed and the document is a formal communication of that transcript, the classification is CT with high confidence.
2026-05-18 English
FORM 6-K
Regulatory Filings
2026-05-18 English
FORM 6-K
Regulatory Filings
2026-05-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.